AIMS: We aimed to asses the generalizability of two 'all-comers' randomized clinical trials (AC-RCTs) in patients undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: Recently two large AC-RCT's comparing drug-eluting stents were performed in our institution (LEADERS and RESOLUTE-III). During the inclusion period of these trials 1242 consecutive PCI patients were treated of whom 579 (48%) were actually included. The most important reasons for non-participation were inability to provide informed consent (33.5%), refused to participate (19%), or patient met one of the other exclusion criteria (26.9%). Trial participants more frequently had stable angina (42.5 vs. 34.4%) and less frequently acute myocardial infarction as indication for PCI (31.4 vs. 42.4%) than non-participants. Hypertension (52.8 vs. 49.1%) and hypercholesterolaemia (56.3 vs. 49.1%) were seen more frequently in trial participants; heart failure was less common (2.1 vs. 4.4%). A significant difference in 30-day mortality was observed between AC-RCT participants and non-participants [0.7 vs. 4.5% events; adjusted hazard ratio (aHR) 0.18 and 95% confidence interval (CI) 0.06-0.52]. One-year mortality was also lower (3.1 vs. 6.9% events; aHR: 0.51 and 95% CI: 0.29-0.91, but 1-year mortality in 48 h survivors was similar (3.1 vs. 4.2% events; aHR: 0.74 and 95% CI: 0.41-1.34). CONCLUSION: Applying the all-comers design did not result in inclusion of all consecutive patients, as only half of the target population was enrolled. It should be noted, however, that this design included more patients than observed in classical RCTs. AC-RCT participants and non-participants were different in terms of baseline characteristics and outcome.
RCT Entities:
AIMS: We aimed to asses the generalizability of two 'all-comers' randomized clinical trials (AC-RCTs) in patients undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: Recently two large AC-RCT's comparing drug-eluting stents were performed in our institution (LEADERS and RESOLUTE-III). During the inclusion period of these trials 1242 consecutive PCI patients were treated of whom 579 (48%) were actually included. The most important reasons for non-participation were inability to provide informed consent (33.5%), refused to participate (19%), or patient met one of the other exclusion criteria (26.9%). Trial participants more frequently had stable angina (42.5 vs. 34.4%) and less frequently acute myocardial infarction as indication for PCI (31.4 vs. 42.4%) than non-participants. Hypertension (52.8 vs. 49.1%) and hypercholesterolaemia (56.3 vs. 49.1%) were seen more frequently in trial participants; heart failure was less common (2.1 vs. 4.4%). A significant difference in 30-day mortality was observed between AC-RCT participants and non-participants [0.7 vs. 4.5% events; adjusted hazard ratio (aHR) 0.18 and 95% confidence interval (CI) 0.06-0.52]. One-year mortality was also lower (3.1 vs. 6.9% events; aHR: 0.51 and 95% CI: 0.29-0.91, but 1-year mortality in 48 h survivors was similar (3.1 vs. 4.2% events; aHR: 0.74 and 95% CI: 0.41-1.34). CONCLUSION: Applying the all-comers design did not result in inclusion of all consecutive patients, as only half of the target population was enrolled. It should be noted, however, that this design included more patients than observed in classical RCTs. AC-RCT participants and non-participants were different in terms of baseline characteristics and outcome.
Authors: Robert W Yeh; Matthew J Czarny; Sharon-Lise T Normand; Dean J Kereiakes; David R Holmes; Ralph G Brindis; W Douglas Weaver; John S Rumsfeld; Matthew T Roe; Sunghee Kim; Priscilla Driscoll-Shempp; Laura Mauri Journal: Circ Cardiovasc Qual Outcomes Date: 2014-11-16
Authors: Kanan Patel; Gregg C Fonarow; Dalane W Kitzman; Inmaculada B Aban; Thomas E Love; Richard M Allman; Mihai Gheorghiade; Ali Ahmed Journal: Eur J Heart Fail Date: 2012-07-03 Impact factor: 15.534
Authors: Anna Franzone; Dik Heg; Lorenz Räber; Marco Valgimigli; Raffaele Piccolo; Thomas Zanchin; Kyohei Yamaji; Stefan Stortecky; Stefan Blöchlinger; Lukas Hunziker; Fabien Praz; Peter Jüni; Stephan Windecker; Thomas Pilgrim Journal: Clin Res Cardiol Date: 2016-04-01 Impact factor: 5.460
Authors: Rebekah Gardner; Qijuan Li; Rosa R Baier; Kristen Butterfield; Eric A Coleman; Stefan Gravenstein Journal: J Gen Intern Med Date: 2014-03-04 Impact factor: 5.128
Authors: Selina Vlieger; Gian B Danzi; Floris Kauer; Rohit M Oemrawsingh; Sinisa Stojkovic; Alexander J J IJsselmuiden; Helen Routledge; Peep Laanmets; Marco Roffi; Ole Fröbert; Pascual Baello; Adrian Wlodarczak; Angel Puentes; Jawed Polad; David Hildick-Smith Journal: Coron Artery Dis Date: 2021-08-01 Impact factor: 1.439
Authors: Tim Kinnaird; Mehmood Butt; Fairoz Abdul; Khaled Yazji; Ahmed Hailan; Sean Gallagher; Nicholas Ossei-Gerning; Alexander Chase; Anirban Choudhury; David Smith; Richard Anderson Journal: PLoS One Date: 2016-06-30 Impact factor: 3.240
Authors: Markus Saarijärvi; Lars Wallin; Philip Moons; Hanna Gyllensten; Ewa-Lena Bratt Journal: BMC Med Res Methodol Date: 2020-08-03 Impact factor: 4.615